Jeremy Schafer, PharmD, MBA

Pharma Insights

The Evolution of Value Frameworks and What Is Next

08/19/2019

Larry Blandford, PharmD—Column Editor

Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...

Value...

08/19/2019

Journal of Clinical Pathways

Pharma Insights

The Role of Payers in Antibiotic Stewardship: Facilitating Transitions of Care for Patients With Active Infection

03/15/2017

Jeremy Schafer, PharmD, MBA

All members of the health care community must play a role in antimicrobial stewardship. The payer role is to monitor appropriate antibiotic use, encourage low-cost options, and help to facilitate the transition of...

All...

03/15/2017

Journal of Clinical Pathways

Pharma Insights

Clarity Regarding Prostate Cancer Screening, Why Payers Need It Too

09/06/2016

Jeremy Schafer, PharmD, MBA

Controversy over the lack of a survival benefit associated with early diagnosis of prostate cancer through prostate-specific antigen (PSA) screening has led to uncertainty in the determination of PSA coverage and its...

...

09/06/2016

Journal of Clinical Pathways

Pharma Insights

The Rising Use of Oncology Value Tools By Payers

08/02/2016

Jeremy Schafer, PharmD, MBA

Kellie Rademacher, PharmD

Janet Serluco, MS

Attributing value in the rapidly expanding oncology space is a new challenge to payers looking to introduce a range of novel therapies where older drugs have long dominated. Rising costs across all levels of cancer...

...

08/02/2016

Journal of Clinical Pathways